AdipoGen Life Sciences
IFN-β (mouse) (monomeric):Fc (LALA-PG)-KIH (human) (rec.)
| Product Details | |
|---|---|
| Synonyms | Interferon beta (mouse) (monomeric):Fc (LALA-PG) Knobs-into-Holes (human) (rec.); Interferon beta; Ifnb1; Interferon-β |
| Product Type | Protein |
| Properties | |
| Source/Host | HEK 293 cells. Produced using animal component-free medium. |
| Sequence |
Mouse IFN-β (aa 22-182) is fused at the C-terminus to the Fc portion of human IgG1 (LALA-PG) (Knobs-into-Holes technology) (see reference: J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)). |
| Crossreactivity | Mouse |
| Specificity |
Binds to mouse IFNAR. |
| Biological Activity |
Inhibits the secretion of IL-6 induced by LPS in Raw 264.7 cells. EC50 is 0.7- 5ng/ml. |
| MW | ~ 65-68 kDa and 28kDa (SDS-PAGE) |
| Purity | ≥95% (SDS-PAGE) |
| Endotoxin Content | <0.01 EU/μg protein (LAL test). |
| Concentration | After reconstitution: 1mg/ml |
| Reconstitution | Reconstitute with 50μl endotoxin-free water. |
| Accession Number | P01575 |
| Formulation | Lyophilized. Contains PBS. |
| Protein Negative Control |
Fc (LALA-PG)-KIH (human) IgG1 Control (rec.) (Prod. No. AG-35B-0018) |
| Other Product Data |
Uniprot link P01575: IFN beta (mouse) |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. PBS containing at least 0.1% BSA should be used for further dilutions. |
| Use/Stability |
Stable for at least 6 months after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
| Documents | |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Interferons (IFNs) are a class of cytokines that initiate a cascade of immune responses against pathogens. During an infection, pattern recognition receptors (PRRs) sense pathogen-associated molecular patterns (PAMPs), leading to the induction and secretion of IFNs by infected immune or epithelial cells. IFNs bind IFN receptors on the surface of neighboring and/or immune cells, triggering a signaling cascade to induce a suite of IFN-stimulated genes (ISGs) that directly mediate the anti-pathogenic effects of IFNs. Each type of IFN has its own specificities, such as different receptor utilization, expression patterns and distinct downstream genes. IFN-α and IFN-β are type I IFNs, produced by most cells in response to infection. Type I IFNs bind to their receptor, IFNAR, leading to the phosphorylation of transcription factors (TFs) STAT1 and STAT2, which bind IFN regulatory factor (IRF) 9 to form a complex called the ISG factor 3 (ISGF3). ISGF3 translocates to the nucleus and induces ISGs.
The protein IFN-β (mouse) (monomeric):Fc (LALA-PG)-KIH (human) (rec.) is produced by using two different vectors, one encoding for the IFN-β (mouse):Fc (LALA-PG) Knobs sequence (synthesizing a protein of 65-68 kDa) and one encoding for the Fc (LALA-PG) Holes sequence (synthesizing a protein of 28 kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization of the Fc moieties and for secretion of the final protein IFN-β (mouse) (monomeric):Fc (LALA-PG)-KIH (human) (rec.). The LALA-PG mutations inhibit binding to FcγRs and C1q, while FcRn binding and Fc stability remain unaffected.
InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences.
